Evaxion A/S EVAX

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $7.5M$3.3M$73.0K$0—————
Operating income -$9.2M-$14.7M-$22.2M-$25.3M-$25.8M-$16.6M-$10.9M-$5.6M—
Net income -$7.7M-$10.6M-$22.1M-$23.2M-$24.5M-$15.0M-$11.2M-$5.5M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets $28.4M$12.5M$12.9M$22.0M$40.2M$12.0M$11.1M——
Total equity $17.0M-$1.7M-$4.7M$8.3M$32.4M$7.0M$9.4M-$931.0K$2.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001171843-26-001346.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 10M Net income, FY2018: -5.5M Net income, FY2019: -11.2M Net income, FY2020: -15M Net income, FY2021: -24.5M Revenue, FY2022: 0 Net income, FY2022: -23.2M Revenue, FY2023: 73K Net income, FY2023: -22.1M Revenue, FY2024: 3.3M Net income, FY2024: -10.6M Revenue, FY2025: 7.5M Net income, FY2025: -7.7M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — $0 $73.0K $3.3M $7.5M
Gross profit — — — — — — — — —
Net income — -$5.5M -$11.2M -$15.0M -$24.5M -$23.2M -$22.1M -$10.6M -$7.7M

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%